Pazopanib for the maintenance treatment of epithelial ovarian, fallopian and peritoneal cancer in patients whose disease has not progressed after first line therapy
 
Status Suspended
Decision Selected
Process STA pre-2018
Referral date 01 October 2013
Topic area
  • Cancer
  • Gynaecology, pregnancy and birth
Description

Scoped as part of Batch 31

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager:

TBC
Technical Lead: TBC

Timeline

Key events during the development of the guidance:

Date Update
14 April 2014 As you will be aware, the Department of Health has asked the Institute to conduct an appraisal of pazopanib for the maintenance treatment of epithelial ovarian, fallopian and peritoneal cancer in patients whose disease has not progressed after first line therapy .
The Institute has now been informed by the manufacturer that it will no longer be pursuing a licensing application for pazopanib in this indication, therefore, NICE has decided to suspend this appraisal on its current work programme.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

For further information on our processes and methods, please see our CHTE processes and methods manual